摘要: GSK investors call for chairman's head after sorry Q2, bribery probesSeptember 2, 2014 | By Tracy StatonGlaxoSmithKline Chairman Christopher Gent says he'll step down at the end of 2015. But thanks to ...
GSK investors call for chairman's head after sorry Q2, bribery probes September 2, 2014 | By Tracy Staton GlaxoSmithKline Chairman Christopher Gent says he'll step down at the end of 2015. But thanks to sweeping corruption allegations and a languishing stock price, shareholders want change at the top now, the Sunday Times reports. "They want the chairman or chief executive gone in 2014," a well-placed source told the Times. "The most obvious choice is Gent, as he will be going, eventually, anyway." According to the Times, top Glaxo ($GSK) investors are plotting a campaign to shake up the company's board. The institutional shareholders may approach the company's senior independent director, Deryck Maughan, to get the ball rolling. Their motivation? Glaxo's ethics problem. Already embroiled in a huge bribery investigation in China, the country recently has announced a series of corruption probes in other countries. At last count, Glaxo faced allegations in at least 10 countries, including Poland, Syria and Lebanon. Officials in the U.K. and U.S. are pursuing their own investigations of the foreign corruption allegations. And that's on top of multibillion-dollar payments to the U.S. government for marketing violations and shoddy manufacturing. The company's recent financial performance hasn't helped, either. Glaxo reported disappointing results for the second quarter, as competition for its top-selling respiratory drug, Advair, dragged down sales. Early results from its follow-ups to Advair, Anoro and Breo, were less than spectacular. The upshot: Glaxo warned that its profits forecast might be too ambitious. GSK's stock price plummeted after its Q2 announcement, to the point where Denmark's Novo Nordisk ($NVO), a much smaller company sales-wise, topped the British drugmaker's market cap. GSK is already scouting for Gent's replacement, with the chairman himself leading the search. Among the top candidates is Philip Hampton, chairman of Royal Bank of Scotland. Maughan has been working with Gent on his replacement as well. Sky News reports that Hampton's appointment could be announced next month. |
我们提供专业的服务, 从产品定位、机械的生产制造,我们 实力出众,只因我们更努力
公司生产的生物反应器及各种配套设备,可替代国外同类产品的垄断,并帮助企业节省生产成本,同时提供生产过程中各种技术支持。
我们一如既往地根据用户的需求、市场环境、企业状况等进行综合分析并提供真实可靠的解决方案,迄今为止服务上千家企业。
我们将致力于优质的技术服务确保每个机械设备的安全,用更成熟的方案解决每一个问题,为企业提供一站式服务。